# Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.

> **NCT02346578** · PHASE2 · COMPLETED · sponsor: **Taro Iguchi, MD, PHD** · enrollment: 104 (actual)

## Conditions studied

- Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Enzalutamide
- **DRUG:** Flutamide

## Key facts

- **NCT ID:** NCT02346578
- **Lead sponsor:** Taro Iguchi, MD, PHD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2018-09-30
- **Final completion:** 2019-01-22
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2021-09-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02346578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02346578, "Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02346578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*